Chalmers R J, Johnson R H, Keogh H J, Nanda R N
J Neurol Neurosurg Psychiatry. 1978 Feb;41(2):135-9. doi: 10.1136/jnnp.41.2.135.
The growth hormone (hGH) and prolactin (hPRL) responses to oral bromocriptine were studied in two groups of patients with Huntington's chorea and in seven healthy control subjects. The patients included six patients who had previously been treated with phenothiazines and six patients who had not received phenothiazine treatment. All medication was stopped 72 hours before the investigation which involved taking blood samples for up to 210 minutes after taking bromocriptine (2.5 mg). Plasma samples were analysed for hGH and hPRL. There was no significant difference in basal hGH concentrations between the patients and control subjects. The hGH response to bromocriptine varied in the individual patients but the concentrations were significantly lower in the patients compared with the controls between 160 and 210 minutes. The basal concentrations of hPRL were also not different, apart from the findings of elevated hPRL concentrations in three patients previously treated with phenothiazines. The patients and control subjects showed a consistent fall in hPRL concentrations after taking bromocriptine. The lower peak hGH response to bromocriptine found in the patients suggests that there may be an alteration of dopaminergic neurones mediating hGH release.
在两组亨廷顿舞蹈症患者以及七名健康对照者中,研究了口服溴隐亭后生长激素(hGH)和催乳素(hPRL)的反应。患者包括六名曾接受吩噻嗪治疗的患者和六名未接受过吩噻嗪治疗的患者。在调查前72小时停用所有药物,调查包括在服用溴隐亭(2.5毫克)后长达210分钟采集血样。分析血浆样本中的hGH和hPRL。患者和对照者的基础hGH浓度无显著差异。溴隐亭引起的hGH反应在个体患者中有所不同,但在160至210分钟之间,患者的hGH浓度显著低于对照者。除了三名曾接受吩噻嗪治疗的患者hPRL浓度升高外,基础hPRL浓度也无差异。患者和对照者在服用溴隐亭后hPRL浓度均出现一致下降。患者中发现的对溴隐亭较低的hGH峰值反应表明,介导hGH释放的多巴胺能神经元可能发生了改变。